dbSNP Short Genetic Variations
Welcome to the Reference SNP (rs) Report
All alleles are reported in the Forward orientation. Click on the Variant Details tab for details on Genomic Placement, Gene, and Amino Acid changes. HGVS names are in the HGVS tab.
Reference SNP (rs) Report
This page reports data for a single dbSNP Reference SNP variation (RefSNP or rs) from the new redesigned dbSNP build.
Top of the page reports a concise summary for the rs, with more specific details included in the corresponding tabs below.
All alleles are reported in the Forward orientation. Use the Genomic View to inspect the nucleotides flanking the variant, and its neighbors.
For more information see Help documentation.
rs12248560
Current Build 157
Released September 3, 2024
- Organism
- Homo sapiens
- Position
-
chr10:94761900 (GRCh38.p14) Help
The anchor position for this RefSNP. Includes all nucleotides potentially affected by this change, thus it can differ from HGVS, which is right-shifted. See here for details.
- Alleles
- C>A / C>T
- Variation Type
- SNV Single Nucleotide Variation
- Frequency
-
T=0.196037 (51889/264690, TOPMED)T=0.199616 (29726/148916, GnomAD_genomes)T=0.01009 (781/77438, 38KJPN) (+ 18 more)
- Clinical Significance
- Reported in ClinVar
- Gene : Consequence
- CYP2C19 : 2KB Upstream Variant
- Publications
- 125 citations
- Genomic View
- See rs on genome
ALFA Allele Frequency
The ALFA project provide aggregate allele frequency from dbGaP. More information is available on the project page including descriptions, data access, and terms of use.
Population | Group | Sample Size | Ref Allele | Alt Allele | Ref HMOZ | Alt HMOZ | HTRZ | HWEP |
---|---|---|---|---|---|---|---|---|
Total | Global | 18890 | C=0.77771 | T=0.22229 | 0.606564 | 0.051138 | 0.342298 | 1 |
European | Sub | 14286 | C=0.76865 | T=0.23135 | 0.590928 | 0.053619 | 0.355453 | 0 |
African | Sub | 2946 | C=0.7736 | T=0.2264 | 0.602851 | 0.055669 | 0.34148 | 1 |
African Others | Sub | 114 | C=0.789 | T=0.211 | 0.614035 | 0.035088 | 0.350877 | 0 |
African American | Sub | 2832 | C=0.7730 | T=0.2270 | 0.602401 | 0.056497 | 0.341102 | 1 |
Asian | Sub | 112 | C=0.982 | T=0.018 | 0.964286 | 0.0 | 0.035714 | 0 |
East Asian | Sub | 86 | C=0.99 | T=0.01 | 0.976744 | 0.0 | 0.023256 | 0 |
Other Asian | Sub | 26 | C=0.96 | T=0.04 | 0.923077 | 0.0 | 0.076923 | 0 |
Latin American 1 | Sub | 146 | C=0.836 | T=0.164 | 0.684932 | 0.013699 | 0.30137 | 0 |
Latin American 2 | Sub | 610 | C=0.897 | T=0.103 | 0.803279 | 0.009836 | 0.186885 | 0 |
South Asian | Sub | 98 | C=0.93 | T=0.07 | 0.857143 | 0.0 | 0.142857 | 0 |
Other | Sub | 692 | C=0.811 | T=0.189 | 0.66185 | 0.040462 | 0.297688 | 0 |
Frequency tab displays a table of the reference and alternate allele frequencies reported by various studies and populations. Table lines, where Population="Global" refer to the entire study population, whereas lines, where Group="Sub", refer to a study-specific population subgroupings (i.e. AFR, CAU, etc.), if available. Frequency for the alternate allele (Alt Allele) is a ratio of samples observed-to-total, where the numerator (observed samples) is the number of chromosomes in the study with the minor allele present (found in "Sample size", where Group="Sub"), and the denominator (total samples) is the total number of all chromosomes in the study for the variant (found in "Sample size", where Group="Study-wide" and Population="Global").
DownloadStudy | Population | Group | Sample Size | Ref Allele | Alt Allele |
---|---|---|---|---|---|
TopMed | Global | Study-wide | 264690 | C=0.803963 | T=0.196037 |
gnomAD v4 - Genomes | Global | Study-wide | 148916 | C=0.800384 | T=0.199616 |
gnomAD v4 - Genomes | European | Sub | 78454 | C=0.78469 | T=0.21531 |
gnomAD v4 - Genomes | African | Sub | 41430 | C=0.77888 | T=0.22112 |
gnomAD v4 - Genomes | American | Sub | 15276 | C=0.86705 | T=0.13295 |
gnomAD v4 - Genomes | East Asian | Sub | 5174 | C=0.9905 | T=0.0095 |
gnomAD v4 - Genomes | South Asian | Sub | 4820 | C=0.8371 | T=0.1629 |
gnomAD v4 - Genomes | Ashkenazi Jewish | Sub | 3468 | C=0.7866 | T=0.2134 |
gnomAD v4 - Genomes | Middle Eastern | sub | 294 | C=0.769 | T=0.231 |
38KJPN | JAPANESE | Study-wide | 77438 | C=0.98991 | T=0.01009 |
Allele Frequency Aggregator | Total | Global | 18890 | C=0.77771 | T=0.22229 |
Allele Frequency Aggregator | European | Sub | 14286 | C=0.76865 | T=0.23135 |
Allele Frequency Aggregator | African | Sub | 2946 | C=0.7736 | T=0.2264 |
Allele Frequency Aggregator | Other | Sub | 692 | C=0.811 | T=0.189 |
Allele Frequency Aggregator | Latin American 2 | Sub | 610 | C=0.897 | T=0.103 |
Allele Frequency Aggregator | Latin American 1 | Sub | 146 | C=0.836 | T=0.164 |
Allele Frequency Aggregator | Asian | Sub | 112 | C=0.982 | T=0.018 |
Allele Frequency Aggregator | South Asian | Sub | 98 | C=0.93 | T=0.07 |
Korean Genome Project 4K | KOREAN | Study-wide | 7232 | C=0.9891 | T=0.0109 |
1000Genomes_30X | Global | Study-wide | 6404 | C=0.8407 | T=0.1593 |
1000Genomes_30X | African | Sub | 1786 | C=0.7637 | T=0.2363 |
1000Genomes_30X | Europe | Sub | 1266 | C=0.7757 | T=0.2243 |
1000Genomes_30X | South Asian | Sub | 1202 | C=0.8519 | T=0.1481 |
1000Genomes_30X | East Asian | Sub | 1170 | C=0.9846 | T=0.0154 |
1000Genomes_30X | American | Sub | 980 | C=0.880 | T=0.120 |
1000Genomes | Global | Study-wide | 5008 | C=0.8468 | T=0.1532 |
1000Genomes | African | Sub | 1322 | C=0.7648 | T=0.2352 |
1000Genomes | East Asian | Sub | 1008 | C=0.9851 | T=0.0149 |
1000Genomes | Europe | Sub | 1006 | C=0.7763 | T=0.2237 |
1000Genomes | South Asian | Sub | 978 | C=0.864 | T=0.136 |
1000Genomes | American | Sub | 694 | C=0.880 | T=0.120 |
Genetic variation in the Estonian population | Estonian | Study-wide | 4480 | C=0.7400 | T=0.2600 |
The Avon Longitudinal Study of Parents and Children | PARENT AND CHILD COHORT | Study-wide | 3854 | C=0.7911 | T=0.2089 |
UK 10K study - Twins | TWIN COHORT | Study-wide | 3708 | C=0.7683 | T=0.2317 |
KOREAN population from KRGDB | KOREAN | Study-wide | 2922 | C=0.9918 | T=0.0082 |
Korean Genome Project | KOREAN | Study-wide | 1832 | C=0.9896 | T=0.0104 |
Genome of the Netherlands Release 5 | Genome of the Netherlands | Study-wide | 998 | C=0.763 | T=0.237 |
CNV burdens in cranial meningiomas | Global | Study-wide | 790 | C=0.984 | T=0.016 |
CNV burdens in cranial meningiomas | CRM | Sub | 790 | C=0.984 | T=0.016 |
Northern Sweden | ACPOP | Study-wide | 600 | C=0.815 | T=0.185 |
HapMap | Global | Study-wide | 330 | C=0.821 | T=0.179 |
HapMap | African | Sub | 120 | C=0.725 | T=0.275 |
HapMap | American | Sub | 120 | C=0.783 | T=0.217 |
HapMap | Asian | Sub | 90 | C=1.00 | T=0.00 |
Qatari | Global | Study-wide | 216 | C=0.796 | T=0.204 |
A Vietnamese Genetic Variation Database | Global | Study-wide | 216 | C=0.995 | T=0.005 |
SGDP_PRJ | Global | Study-wide | 114 | C=0.447 | T=0.553 |
The Danish reference pan genome | Danish | Study-wide | 40 | C=0.75 | T=0.25 |
Siberian | Global | Study-wide | 16 | C=0.31 | T=0.69 |
Variant Details tab shows known variant placements on genomic sequences: chromosomes (NC_), RefSeqGene, pseudogenes or genomic regions (NG_), and in a separate table: on transcripts (NM_) and protein sequences (NP_). The corresponding transcript and protein locations are listed in adjacent lines, along with molecular consequences from Sequence Ontology. When no protein placement is available, only the transcript is listed. Column "Codon[Amino acid]" shows the actual base change in the format of "Reference > Alternate" allele, including the nucleotide codon change in transcripts, and the amino acid change in proteins, respectively, allowing for known ribosomal slippage sites. To view nucleotides adjacent to the variant use the Genomic View at the bottom of the page - zoom into the sequence until the nucleotides around the variant become visible.
Sequence name | Change |
---|---|
GRCh38.p14 chr 10 | NC_000010.11:g.94761900C>A |
GRCh38.p14 chr 10 | NC_000010.11:g.94761900C>T |
GRCh37.p13 chr 10 | NC_000010.10:g.96521657C>A |
GRCh37.p13 chr 10 | NC_000010.10:g.96521657C>T |
CYP2C19 RefSeqGene (LRG_584) | NG_008384.3:g.4220C>A |
CYP2C19 RefSeqGene (LRG_584) | NG_008384.3:g.4220C>T |
LOC110599570 genomic region | NG_055436.1:g.1260C>A |
LOC110599570 genomic region | NG_055436.1:g.1260C>T |
Molecule type | Change | Amino acid[Codon] | SO Term |
---|---|---|---|
CYP2C19 transcript | NM_000769.4:c. | N/A | Upstream Transcript Variant |
Clinical Significance tab shows a list of clinical significance entries from ClinVar associated with the variation, per allele. Click on the RCV accession (i.e. RCV000001615.2) or Allele ID (i.e. 12274) to access full ClinVar report.
ClinVar Accession | Disease Names | Clinical Significance |
---|---|---|
RCV000326411.15 | not provided | Benign,Other |
RCV000782438.10 | CYP2C19: increased function | Drug-Response |
RCV000782443.10 | Clopidogrel response | Drug-Response |
RCV000782446.11 | Clopidogrel response | Drug-Response |
RCV000782447.11 | Clopidogrel response | Drug-Response |
RCV000782451.10 | Clopidogrel response | Drug-Response |
RCV000782454.10 | Clopidogrel response | Drug-Response |
RCV000782459.11 | Clopidogrel response | Drug-Response |
RCV000782460.10 | Clopidogrel response | Drug-Response |
RCV000782461.10 | Clopidogrel response | Drug-Response |
RCV000782462.12 | Clopidogrel response | Drug-Response |
RCV000782463.11 | Clopidogrel response | Drug-Response |
RCV000782492.10 | Citalopram response | Drug-Response |
RCV000782493.10 | Escitalopram response | Drug-Response |
RCV000782505.11 | Escitalopram response | Drug-Response |
RCV000782506.11 | Citalopram response | Drug-Response |
RCV000782507.11 | Escitalopram response | Drug-Response |
RCV000782508.11 | Citalopram response | Drug-Response |
RCV000782509.11 | Escitalopram response | Drug-Response |
RCV000782514.11 | Citalopram response | Drug-Response |
RCV000782515.11 | Escitalopram response | Drug-Response |
RCV000782524.11 | Citalopram response | Drug-Response |
RCV000782525.11 | Escitalopram response | Drug-Response |
RCV000782529.10 | Escitalopram response | Drug-Response |
RCV000782534.10 | Citalopram response | Drug-Response |
RCV000782535.10 | Escitalopram response | Drug-Response |
RCV000782536.10 | Citalopram response | Drug-Response |
RCV000782537.10 | Escitalopram response | Drug-Response |
RCV000782544.11 | Citalopram response | Drug-Response |
RCV000782548.11 | Citalopram response | Drug-Response |
RCV000782549.11 | Escitalopram response | Drug-Response |
RCV000782553.11 | Escitalopram response | Drug-Response |
RCV000782575.11 | Citalopram response | Drug-Response |
RCV000782576.11 | Escitalopram response | Drug-Response |
RCV000782600.11 | Citalopram response | Drug-Response |
RCV000782658.10 | Escitalopram response | Drug-Response |
RCV000782659.10 | Citalopram response | Drug-Response |
RCV000782660.10 | Escitalopram response | Drug-Response |
RCV000782661.10 | Citalopram response | Drug-Response |
RCV000782662.10 | Escitalopram response | Drug-Response |
RCV000782663.10 | Citalopram response | Drug-Response |
RCV000782664.10 | Escitalopram response | Drug-Response |
RCV000782713.10 | Citalopram response | Drug-Response |
RCV000782714.10 | Escitalopram response | Drug-Response |
RCV000782724.10 | Citalopram response | Drug-Response |
RCV000782726.10 | Citalopram response | Drug-Response |
RCV000782727.10 | Escitalopram response | Drug-Response |
RCV000782728.10 | Citalopram response | Drug-Response |
RCV000782729.10 | Escitalopram response | Drug-Response |
RCV000782730.10 | Citalopram response | Drug-Response |
RCV000782731.10 | Escitalopram response | Drug-Response |
RCV000782732.11 | Citalopram response | Drug-Response |
RCV000782733.10 | Escitalopram response | Drug-Response |
RCV000782792.11 | Escitalopram response | Drug-Response |
RCV000782857.11 | Citalopram response | Drug-Response |
RCV000782858.11 | Escitalopram response | Drug-Response |
RCV000782859.11 | Citalopram response | Drug-Response |
RCV000782860.11 | Escitalopram response | Drug-Response |
RCV000782861.11 | Citalopram response | Drug-Response |
RCV000782862.11 | Escitalopram response | Drug-Response |
RCV000782863.11 | Citalopram response | Drug-Response |
RCV000782864.11 | Escitalopram response | Drug-Response |
RCV000782992.10 | Citalopram response | Drug-Response |
RCV000782993.10 | Escitalopram response | Drug-Response |
RCV000782994.10 | Citalopram response | Drug-Response |
RCV000782995.10 | Escitalopram response | Drug-Response |
RCV000782996.10 | Citalopram response | Drug-Response |
RCV000782997.10 | Escitalopram response | Drug-Response |
RCV000782998.10 | Citalopram response | Drug-Response |
RCV000782999.10 | Escitalopram response | Drug-Response |
RCV000783000.10 | Citalopram response | Drug-Response |
RCV000783049.11 | Escitalopram response | Drug-Response |
RCV000783050.11 | Citalopram response | Drug-Response |
RCV000783051.11 | Escitalopram response | Drug-Response |
RCV000783052.11 | Citalopram response | Drug-Response |
RCV000783053.11 | Escitalopram response | Drug-Response |
RCV000783054.11 | Citalopram response | Drug-Response |
RCV000783055.11 | Escitalopram response | Drug-Response |
RCV000783056.11 | Citalopram response | Drug-Response |
RCV000783071.10 | Sertraline response | Drug-Response |
RCV000783077.11 | Sertraline response | Drug-Response |
RCV000783078.11 | Sertraline response | Drug-Response |
RCV000783079.11 | Sertraline response | Drug-Response |
RCV000783087.11 | Sertraline response | Drug-Response |
RCV000783090.10 | Sertraline response | Drug-Response |
RCV000783091.10 | Sertraline response | Drug-Response |
RCV000783091.10 | Sertraline response | Drug-Response |
RCV000783092.10 | Sertraline response | Drug-Response |
RCV000783093.10 | Sertraline response | Drug-Response |
RCV000783097.11 | Sertraline response | Drug-Response |
RCV000783101.11 | Sertraline response | Drug-Response |
RCV000783112.11 | Sertraline response | Drug-Response |
RCV000783122.11 | Sertraline response | Drug-Response |
RCV000783123.11 | Sertraline response | Drug-Response |
RCV000783131.11 | Sertraline response | Drug-Response |
RCV000783171.10 | Sertraline response | Drug-Response |
RCV000783187.10 | Sertraline response | Drug-Response |
RCV000783188.10 | Sertraline response | Drug-Response |
RCV000783189.10 | Sertraline response | Drug-Response |
RCV000783190.10 | Sertraline response | Drug-Response |
RCV000783191.10 | Sertraline response | Drug-Response |
RCV000783223.11 | Sertraline response | Drug-Response |
RCV000783254.11 | Sertraline response | Drug-Response |
RCV000783255.11 | Sertraline response | Drug-Response |
RCV000783256.11 | Sertraline response | Drug-Response |
RCV000783257.11 | Sertraline response | Drug-Response |
RCV000783258.11 | Sertraline response | Drug-Response |
RCV000783259.11 | Sertraline response | Drug-Response |
RCV000783260.11 | Sertraline response | Drug-Response |
RCV000783325.10 | Sertraline response | Drug-Response |
RCV000783326.10 | Sertraline response | Drug-Response |
RCV000783372.11 | Voriconazole response | Drug-Response |
RCV000783384.11 | Voriconazole response | Drug-Response |
RCV000783401.11 | Voriconazole response | Drug-Response |
RCV000783402.11 | Voriconazole response | Drug-Response |
RCV000783403.11 | Voriconazole response | Drug-Response |
RCV000783404.11 | Voriconazole response | Drug-Response |
RCV000783405.11 | Voriconazole response | Drug-Response |
RCV000783406.11 | Voriconazole response | Drug-Response |
RCV000783472.10 | Voriconazole response | Drug-Response |
RCV000783473.10 | Voriconazole response | Drug-Response |
RCV000783512.11 | Voriconazole response | Drug-Response |
RCV000783513.11 | Voriconazole response | Drug-Response |
RCV000783523.10 | Voriconazole response | Drug-Response |
RCV000783524.10 | Voriconazole response | Drug-Response |
RCV000783525.10 | Voriconazole response | Drug-Response |
RCV000783526.10 | Voriconazole response | Drug-Response |
RCV000783526.10 | Voriconazole response | Drug-Response |
RCV000783527.10 | Voriconazole response | Drug-Response |
RCV000783528.10 | Voriconazole response | Drug-Response |
RCV000783530.11 | Voriconazole response | Drug-Response |
RCV000783536.11 | Voriconazole response | Drug-Response |
RCV000783557.11 | Voriconazole response | Drug-Response |
RCV000783558.11 | Voriconazole response | Drug-Response |
RCV000783559.11 | Voriconazole response | Drug-Response |
RCV000783568.11 | Voriconazole response | Drug-Response |
RCV000783587.10 | Voriconazole response | Drug-Response |
RCV000783588.10 | Voriconazole response | Drug-Response |
RCV000783617.10 | Voriconazole response | Drug-Response |
RCV000783622.10 | Voriconazole response | Drug-Response |
RCV000783630.10 | Voriconazole response | Drug-Response |
RCV000783631.11 | Voriconazole response | Drug-Response |
RCV000783632.10 | Voriconazole response | Drug-Response |
RCV000783633.10 | Voriconazole response | Drug-Response |
RCV000783634.10 | Voriconazole response | Drug-Response |
RCV000783635.10 | Voriconazole response | Drug-Response |
RCV000783649.11 | CYP2C19: no function | Drug-Response |
RCV000783666.11 | Clopidogrel response | Drug-Response |
RCV000783667.11 | Clopidogrel response | Drug-Response |
RCV000783668.10 | Clopidogrel response | Drug-Response |
RCV000783669.10 | Clopidogrel response | Drug-Response |
RCV000783669.10 | Clopidogrel response | Drug-Response |
RCV000783670.11 | Clopidogrel response | Drug-Response |
RCV000783671.11 | Clopidogrel response | Drug-Response |
RCV000783676.10 | Clopidogrel response | Drug-Response |
RCV000783682.10 | Clopidogrel response | Drug-Response |
RCV000783683.10 | Clopidogrel response | Drug-Response |
RCV000783735.11 | Citalopram response | Drug-Response |
RCV000783759.10 | Citalopram response | Drug-Response |
RCV000783760.10 | Escitalopram response | Drug-Response |
RCV000783761.10 | Citalopram response | Drug-Response |
RCV000783762.10 | Escitalopram response | Drug-Response |
RCV000783763.10 | Citalopram response | Drug-Response |
RCV000783763.10 | Citalopram response | Drug-Response |
RCV000783764.10 | Escitalopram response | Drug-Response |
RCV000783764.10 | Escitalopram response | Drug-Response |
RCV000783765.10 | Citalopram response | Drug-Response |
RCV000783766.10 | Escitalopram response | Drug-Response |
RCV000783767.10 | Citalopram response | Drug-Response |
RCV000783768.11 | Escitalopram response | Drug-Response |
RCV000783783.11 | Citalopram response | Drug-Response |
RCV000783787.11 | Citalopram response | Drug-Response |
RCV000783788.11 | Escitalopram response | Drug-Response |
RCV000783821.11 | Citalopram response | Drug-Response |
RCV000783822.11 | Escitalopram response | Drug-Response |
RCV000783826.11 | Escitalopram response | Drug-Response |
RCV000783827.11 | Citalopram response | Drug-Response |
RCV000783828.11 | Escitalopram response | Drug-Response |
RCV000783829.11 | Citalopram response | Drug-Response |
RCV000783830.11 | Escitalopram response | Drug-Response |
RCV000783848.11 | Citalopram response | Drug-Response |
RCV000783849.11 | Escitalopram response | Drug-Response |
RCV000783888.10 | Citalopram response | Drug-Response |
RCV000783889.10 | Escitalopram response | Drug-Response |
RCV000783890.10 | Citalopram response | Drug-Response |
RCV000783891.10 | Escitalopram response | Drug-Response |
RCV000783892.10 | Citalopram response | Drug-Response |
RCV000783926.10 | Citalopram response | Drug-Response |
RCV000783927.10 | Escitalopram response | Drug-Response |
RCV000783950.10 | Escitalopram response | Drug-Response |
RCV000783958.11 | Escitalopram response | Drug-Response |
RCV000783959.10 | Citalopram response | Drug-Response |
RCV000783960.10 | Escitalopram response | Drug-Response |
RCV000783961.10 | Citalopram response | Drug-Response |
RCV000783962.10 | Escitalopram response | Drug-Response |
RCV000783963.10 | Citalopram response | Drug-Response |
RCV000783964.10 | Escitalopram response | Drug-Response |
RCV000783965.10 | Citalopram response | Drug-Response |
RCV000783985.12 | Citalopram response | Drug-Response |
RCV000783986.12 | Escitalopram response | Drug-Response |
RCV000784024.11 | Citalopram response | Drug-Response |
RCV000784049.11 | Citalopram response | Drug-Response |
RCV000784050.11 | Escitalopram response | Drug-Response |
RCV000784083.11 | Citalopram response | Drug-Response |
RCV000784084.11 | Escitalopram response | Drug-Response |
RCV000784085.11 | Citalopram response | Drug-Response |
RCV000784086.11 | Escitalopram response | Drug-Response |
RCV000784087.11 | Citalopram response | Drug-Response |
RCV000784088.11 | Escitalopram response | Drug-Response |
RCV000784089.11 | Citalopram response | Drug-Response |
RCV000784090.11 | Escitalopram response | Drug-Response |
RCV000784222.10 | Escitalopram response | Drug-Response |
RCV000784223.10 | Citalopram response | Drug-Response |
RCV000784224.10 | Escitalopram response | Drug-Response |
RCV000784225.10 | Citalopram response | Drug-Response |
RCV000784226.10 | Escitalopram response | Drug-Response |
RCV000784227.10 | Citalopram response | Drug-Response |
RCV000784228.10 | Escitalopram response | Drug-Response |
RCV000784229.10 | Citalopram response | Drug-Response |
RCV000784230.10 | Escitalopram response | Drug-Response |
RCV000784231.10 | Citalopram response | Drug-Response |
RCV000784232.10 | Escitalopram response | Drug-Response |
RCV000784285.11 | Citalopram response | Drug-Response |
RCV000784286.11 | Escitalopram response | Drug-Response |
RCV000784287.11 | Citalopram response | Drug-Response |
RCV000784288.11 | Escitalopram response | Drug-Response |
RCV000784315.11 | Sertraline response | Drug-Response |
RCV000784322.10 | Sertraline response | Drug-Response |
RCV000784325.10 | Sertraline response | Drug-Response |
RCV000784326.10 | Sertraline response | Drug-Response |
RCV000784332.11 | Sertraline response | Drug-Response |
RCV000784336.11 | Sertraline response | Drug-Response |
RCV000784353.11 | Sertraline response | Drug-Response |
RCV000784359.11 | Sertraline response | Drug-Response |
RCV000784386.10 | Sertraline response | Drug-Response |
RCV000784387.10 | Sertraline response | Drug-Response |
RCV000784388.10 | Sertraline response | Drug-Response |
RCV000784389.10 | Sertraline response | Drug-Response |
RCV000784390.10 | Sertraline response | Drug-Response |
RCV000784391.10 | Sertraline response | Drug-Response |
RCV000784415.10 | Sertraline response | Drug-Response |
RCV000784421.10 | Sertraline response | Drug-Response |
RCV000784422.10 | Sertraline response | Drug-Response |
RCV000784423.10 | Sertraline response | Drug-Response |
RCV000784424.11 | Sertraline response | Drug-Response |
RCV000784433.12 | Sertraline response | Drug-Response |
RCV000784435.11 | Sertraline response | Drug-Response |
RCV000784436.11 | Sertraline response | Drug-Response |
RCV000784437.11 | Sertraline response | Drug-Response |
RCV000784438.11 | Sertraline response | Drug-Response |
RCV000784439.11 | Sertraline response | Drug-Response |
RCV000784440.11 | Sertraline response | Drug-Response |
RCV000784472.11 | Sertraline response | Drug-Response |
RCV000784489.11 | Sertraline response | Drug-Response |
RCV000784549.12 | Voriconazole response | Drug-Response |
RCV000784557.10 | Sertraline response | Drug-Response |
RCV000784558.10 | Sertraline response | Drug-Response |
RCV000784559.10 | Sertraline response | Drug-Response |
RCV000784560.10 | Sertraline response | Drug-Response |
RCV000784561.10 | Sertraline response | Drug-Response |
RCV000784562.10 | Sertraline response | Drug-Response |
RCV000784563.10 | Sertraline response | Drug-Response |
RCV000784564.10 | Sertraline response | Drug-Response |
RCV000784638.11 | Voriconazole response | Drug-Response |
RCV000784639.11 | Voriconazole response | Drug-Response |
RCV000784705.10 | Voriconazole response | Drug-Response |
RCV000784706.10 | Voriconazole response | Drug-Response |
RCV000784707.10 | Voriconazole response | Drug-Response |
RCV000784708.10 | Voriconazole response | Drug-Response |
RCV000784709.10 | Voriconazole response | Drug-Response |
RCV000784710.10 | Voriconazole response | Drug-Response |
RCV000784711.10 | Voriconazole response | Drug-Response |
RCV000784712.10 | Voriconazole response | Drug-Response |
RCV000784737.10 | Voriconazole response | Drug-Response |
RCV000784745.11 | Voriconazole response | Drug-Response |
RCV000784752.11 | Voriconazole response | Drug-Response |
RCV000784753.11 | Voriconazole response | Drug-Response |
RCV000784759.10 | Voriconazole response | Drug-Response |
RCV000784763.11 | Voriconazole response | Drug-Response |
RCV000784773.11 | Voriconazole response | Drug-Response |
RCV000784779.11 | Voriconazole response | Drug-Response |
RCV000784789.11 | Voriconazole response | Drug-Response |
RCV000784809.10 | Voriconazole response | Drug-Response |
RCV000784810.10 | Voriconazole response | Drug-Response |
RCV000784811.10 | Voriconazole response | Drug-Response |
RCV000784812.10 | Voriconazole response | Drug-Response |
RCV000784851.10 | Voriconazole response | Drug-Response |
RCV000784856.10 | Voriconazole response | Drug-Response |
RCV000784857.10 | Voriconazole response | Drug-Response |
RCV000784868.11 | Voriconazole response | Drug-Response |
RCV000784869.11 | Voriconazole response | Drug-Response |
RCV000784870.11 | Voriconazole response | Drug-Response |
RCV000784871.11 | Voriconazole response | Drug-Response |
RCV000784872.11 | Voriconazole response | Drug-Response |
RCV000784873.11 | Voriconazole response | Drug-Response |
Aliases tab displays HGVS names representing the variant placements and allele changes on genomic, transcript and protein sequences, per allele. HGVS name is an expression for reporting sequence accession and version, sequence type, position, and allele change. The column "Note" can have two values: "diff" means that there is a difference between the reference allele (variation interval) at the placement reported in HGVS name and the reference alleles reported in other HGVS names, and "rev" means that the sequence of this variation interval at the placement reported in HGVS name is in reverse orientation to the sequence(s) of this variation in other HGVS names not labeled as "rev".
Placement | C= | A | T |
---|---|---|---|
GRCh38.p14 chr 10 | NC_000010.11:g.94761900= | NC_000010.11:g.94761900C>A | NC_000010.11:g.94761900C>T |
GRCh37.p13 chr 10 | NC_000010.10:g.96521657= | NC_000010.10:g.96521657C>A | NC_000010.10:g.96521657C>T |
CYP2C19 RefSeqGene (LRG_584) | NG_008384.3:g.4220= | NG_008384.3:g.4220C>A | NG_008384.3:g.4220C>T |
LOC110599570 genomic region | NG_055436.1:g.1260= | NG_055436.1:g.1260C>A | NG_055436.1:g.1260C>T |
Submissions tab displays variations originally submitted to dbSNP, now supporting this RefSNP cluster (rs). We display Submitter handle, Submission identifier, Date and Build number, when the submission appeared for the first time. Direct submissions to dbSNP have Submission ID in the form of an ss-prefixed number (ss#). Other supporting variations are listed in the table without ss#.
No | Submitter | Submission ID | Date (Build) |
---|---|---|---|
1 | SC_SNP | ss18627820 | Feb 28, 2004 (120) |
2 | SSAHASNP | ss20629041 | Apr 05, 2004 (121) |
3 | PERLEGEN | ss24554293 | Sep 20, 2004 (123) |
4 | EGP_SNPS | ss28531395 | Dec 02, 2004 (126) |
5 | ABI | ss39719499 | Mar 10, 2006 (126) |
6 | HUMANGENOME_JCVI | ss97675639 | Feb 06, 2009 (130) |
7 | 1000GENOMES | ss113672527 | Jan 25, 2009 (130) |
8 | ENSEMBL | ss137888305 | Dec 01, 2009 (131) |
9 | JIPGENE | ss158145861 | Dec 01, 2009 (131) |
10 | JIPGENE | ss158145862 | Dec 01, 2009 (131) |
11 | JIPGENE | ss158145863 | Dec 01, 2009 (131) |
12 | COMPLETE_GENOMICS | ss170776165 | Jul 04, 2010 (132) |
13 | 1000GENOMES | ss224884168 | Jul 14, 2010 (132) |
14 | 1000GENOMES | ss235292619 | Jul 15, 2010 (132) |
15 | GMI | ss280732303 | May 04, 2012 (137) |
16 | GMI | ss286243779 | Apr 25, 2013 (138) |
17 | PJP | ss290909204 | May 09, 2011 (134) |
18 | TISHKOFF | ss562142848 | Apr 25, 2013 (138) |
19 | SSMP | ss657183816 | Apr 25, 2013 (138) |
20 | EVA-GONL | ss987804334 | Aug 21, 2014 (142) |
21 | JMKIDD_LAB | ss1077215281 | Aug 21, 2014 (142) |
22 | 1000GENOMES | ss1338622991 | Aug 21, 2014 (142) |
23 | DDI | ss1426411098 | Apr 01, 2015 (144) |
24 | CLINVAR | ss1457608700 | Nov 23, 2014 (142) |
25 | EVA_GENOME_DK | ss1575296670 | Apr 01, 2015 (144) |
26 | EVA_DECODE | ss1597477658 | Apr 01, 2015 (144) |
27 | EVA_UK10K_ALSPAC | ss1625195760 | Apr 01, 2015 (144) |
28 | EVA_UK10K_TWINSUK | ss1668189793 | Apr 01, 2015 (144) |
29 | WEILL_CORNELL_DGM | ss1931170324 | Feb 12, 2016 (147) |
30 | JJLAB | ss2026313586 | Sep 14, 2016 (149) |
31 | CLINVAR | ss2137495309 | Feb 23, 2017 (149) |
32 | MYSEQ1_SNP | ss2137544432 | Nov 01, 2024 (157) |
33 | EVA | ss2137544462 | Nov 01, 2024 (157) |
34 | USC_VALOUEV | ss2154590234 | Nov 08, 2017 (151) |
35 | HUMAN_LONGEVITY | ss2177147096 | Dec 20, 2016 (150) |
36 | GRF | ss2698842972 | Nov 08, 2017 (151) |
37 | GNOMAD | ss2892126623 | Nov 08, 2017 (151) |
38 | SWEGEN | ss3006965807 | Nov 08, 2017 (151) |
39 | BIOINF_KMB_FNS_UNIBA | ss3026946906 | Nov 08, 2017 (151) |
40 | CSHL | ss3349261213 | Nov 08, 2017 (151) |
41 | URBANLAB | ss3649441543 | Oct 12, 2018 (152) |
42 | EGCUT_WGS | ss3674377968 | Jul 13, 2019 (153) |
43 | EVA_DECODE | ss3690461668 | Jul 13, 2019 (153) |
44 | ACPOP | ss3737585473 | Jul 13, 2019 (153) |
45 | EVA | ss3748468190 | Jul 13, 2019 (153) |
46 | KHV_HUMAN_GENOMES | ss3813834340 | Jul 13, 2019 (153) |
47 | EVA | ss3832276807 | Apr 26, 2020 (154) |
48 | SGDP_PRJ | ss3874827278 | Apr 26, 2020 (154) |
49 | KRGDB | ss3922955442 | Apr 26, 2020 (154) |
50 | KOGIC | ss3968458147 | Apr 26, 2020 (154) |
51 | EVA | ss3984639028 | Apr 26, 2021 (155) |
52 | TOPMED | ss4862622612 | Apr 26, 2021 (155) |
53 | TOMMO_GENOMICS | ss6114200526 | Nov 01, 2024 (157) |
54 | EVA | ss6253826032 | Nov 01, 2024 (157) |
55 | EVA | ss6307409869 | Nov 01, 2024 (157) |
56 | EVA | ss6322395594 | Nov 01, 2024 (157) |
57 | EVA | ss6326442641 | Nov 01, 2024 (157) |
58 | EVA | ss6332060631 | Nov 01, 2024 (157) |
59 | YEGNASUBRAMANIAN_LAB | ss6343187231 | Nov 01, 2024 (157) |
60 | EVA | ss6349787529 | Nov 01, 2024 (157) |
61 | EVA | ss6349997713 | Nov 01, 2024 (157) |
62 | KOGIC | ss6382288653 | Nov 01, 2024 (157) |
63 | GNOMAD | ss6859874352 | Nov 01, 2024 (157) |
64 | TOMMO_GENOMICS | ss8198968530 | Nov 01, 2024 (157) |
65 | EVA | ss8237481891 | Nov 01, 2024 (157) |
66 | EVA | ss8237481892 | Nov 01, 2024 (157) |
67 | EVA | ss8237481893 | Nov 01, 2024 (157) |
68 | 1000G_HIGH_COVERAGE | ss8285087471 | Nov 01, 2024 (157) |
69 | TRAN_CS_UWATERLOO | ss8314429322 | Nov 01, 2024 (157) |
70 | EVA | ss8395322415 | Nov 01, 2024 (157) |
71 | HUGCELL_USP | ss8480547542 | Nov 01, 2024 (157) |
72 | EVA | ss8510129323 | Nov 01, 2024 (157) |
73 | 1000G_HIGH_COVERAGE | ss8579564134 | Nov 01, 2024 (157) |
74 | SANFORD_IMAGENETICS | ss8624255696 | Nov 01, 2024 (157) |
75 | SANFORD_IMAGENETICS | ss8649885623 | Nov 01, 2024 (157) |
76 | TOMMO_GENOMICS | ss8745186048 | Nov 01, 2024 (157) |
77 | EVA | ss8799403694 | Nov 01, 2024 (157) |
78 | YY_MCH | ss8811792280 | Nov 01, 2024 (157) |
79 | EVA | ss8824807337 | Nov 01, 2024 (157) |
80 | EVA | ss8847378107 | Nov 01, 2024 (157) |
81 | EVA | ss8847605615 | Nov 01, 2024 (157) |
82 | EVA | ss8849697092 | Nov 01, 2024 (157) |
83 | EVA | ss8880085382 | Nov 01, 2024 (157) |
84 | EVA | ss8941172158 | Nov 01, 2024 (157) |
85 | EVA | ss8981728040 | Nov 01, 2024 (157) |
86 | EVA | ss8982151818 | Nov 01, 2024 (157) |
87 | 1000Genomes | NC_000010.10 - 96521657 | Oct 12, 2018 (152) |
88 | 1000Genomes_30X | NC_000010.11 - 94761900 | Nov 01, 2024 (157) |
89 | The Avon Longitudinal Study of Parents and Children | NC_000010.10 - 96521657 | Oct 12, 2018 (152) |
90 | Genetic variation in the Estonian population | NC_000010.10 - 96521657 | Oct 12, 2018 (152) |
91 | The Danish reference pan genome | NC_000010.10 - 96521657 | Apr 26, 2020 (154) |
92 | gnomAD v4 - Genomes | NC_000010.11 - 94761900 | Nov 01, 2024 (157) |
93 | Genome of the Netherlands Release 5 | NC_000010.10 - 96521657 | Apr 26, 2020 (154) |
94 | HapMap | NC_000010.11 - 94761900 | Apr 26, 2020 (154) |
95 | KOREAN population from KRGDB | NC_000010.10 - 96521657 | Apr 26, 2020 (154) |
96 | Korean Genome Project | NC_000010.11 - 94761900 | Apr 26, 2020 (154) |
97 | Korean Genome Project 4K | NC_000010.11 - 94761900 | Nov 01, 2024 (157) |
98 | Northern Sweden | NC_000010.10 - 96521657 | Jul 13, 2019 (153) |
99 | CNV burdens in cranial meningiomas | NC_000010.10 - 96521657 | Apr 26, 2021 (155) |
100 | Qatari | NC_000010.10 - 96521657 | Apr 26, 2020 (154) |
101 | SGDP_PRJ | NC_000010.10 - 96521657 | Apr 26, 2020 (154) |
102 | Siberian | NC_000010.10 - 96521657 | Apr 26, 2020 (154) |
103 | 38KJPN | NC_000010.11 - 94761900 | Nov 01, 2024 (157) |
104 | TopMed | NC_000010.11 - 94761900 | Apr 26, 2021 (155) |
105 | UK 10K study - Twins | NC_000010.10 - 96521657 | Oct 12, 2018 (152) |
106 | A Vietnamese Genetic Variation Database | NC_000010.10 - 96521657 | Jul 13, 2019 (153) |
107 | ALFA | NC_000010.11 - 94761900 | Nov 01, 2024 (157) |
108 | ClinVar | RCV000326411.15 | Nov 01, 2024 (157) |
109 | ClinVar | RCV000782438.10 | Nov 01, 2024 (157) |
110 | ClinVar | RCV000782443.10 | Nov 01, 2024 (157) |
111 | ClinVar | RCV000782446.11 | Nov 01, 2024 (157) |
112 | ClinVar | RCV000782447.11 | Nov 01, 2024 (157) |
113 | ClinVar | RCV000782451.10 | Nov 01, 2024 (157) |
114 | ClinVar | RCV000782454.10 | Nov 01, 2024 (157) |
115 | ClinVar | RCV000782459.11 | Nov 01, 2024 (157) |
116 | ClinVar | RCV000782460.10 | Nov 01, 2024 (157) |
117 | ClinVar | RCV000782461.10 | Nov 01, 2024 (157) |
118 | ClinVar | RCV000782462.12 | Nov 01, 2024 (157) |
119 | ClinVar | RCV000782463.11 | Nov 01, 2024 (157) |
120 | ClinVar | RCV000782492.10 | Nov 01, 2024 (157) |
121 | ClinVar | RCV000782493.10 | Nov 01, 2024 (157) |
122 | ClinVar | RCV000782505.11 | Nov 01, 2024 (157) |
123 | ClinVar | RCV000782506.11 | Nov 01, 2024 (157) |
124 | ClinVar | RCV000782507.11 | Nov 01, 2024 (157) |
125 | ClinVar | RCV000782508.11 | Nov 01, 2024 (157) |
126 | ClinVar | RCV000782509.11 | Nov 01, 2024 (157) |
127 | ClinVar | RCV000782514.11 | Nov 01, 2024 (157) |
128 | ClinVar | RCV000782515.11 | Nov 01, 2024 (157) |
129 | ClinVar | RCV000782524.11 | Nov 01, 2024 (157) |
130 | ClinVar | RCV000782525.11 | Nov 01, 2024 (157) |
131 | ClinVar | RCV000782529.10 | Nov 01, 2024 (157) |
132 | ClinVar | RCV000782534.10 | Nov 01, 2024 (157) |
133 | ClinVar | RCV000782535.10 | Nov 01, 2024 (157) |
134 | ClinVar | RCV000782536.10 | Nov 01, 2024 (157) |
135 | ClinVar | RCV000782537.10 | Nov 01, 2024 (157) |
136 | ClinVar | RCV000782544.11 | Nov 01, 2024 (157) |
137 | ClinVar | RCV000782548.11 | Nov 01, 2024 (157) |
138 | ClinVar | RCV000782549.11 | Nov 01, 2024 (157) |
139 | ClinVar | RCV000782553.11 | Nov 01, 2024 (157) |
140 | ClinVar | RCV000782575.11 | Nov 01, 2024 (157) |
141 | ClinVar | RCV000782576.11 | Nov 01, 2024 (157) |
142 | ClinVar | RCV000782600.11 | Nov 01, 2024 (157) |
143 | ClinVar | RCV000782658.10 | Nov 01, 2024 (157) |
144 | ClinVar | RCV000782659.10 | Nov 01, 2024 (157) |
145 | ClinVar | RCV000782660.10 | Nov 01, 2024 (157) |
146 | ClinVar | RCV000782661.10 | Nov 01, 2024 (157) |
147 | ClinVar | RCV000782662.10 | Nov 01, 2024 (157) |
148 | ClinVar | RCV000782663.10 | Nov 01, 2024 (157) |
149 | ClinVar | RCV000782664.10 | Nov 01, 2024 (157) |
150 | ClinVar | RCV000782713.10 | Nov 01, 2024 (157) |
151 | ClinVar | RCV000782714.10 | Nov 01, 2024 (157) |
152 | ClinVar | RCV000782724.10 | Nov 01, 2024 (157) |
153 | ClinVar | RCV000782726.10 | Nov 01, 2024 (157) |
154 | ClinVar | RCV000782727.10 | Nov 01, 2024 (157) |
155 | ClinVar | RCV000782728.10 | Nov 01, 2024 (157) |
156 | ClinVar | RCV000782729.10 | Nov 01, 2024 (157) |
157 | ClinVar | RCV000782730.10 | Nov 01, 2024 (157) |
158 | ClinVar | RCV000782731.10 | Nov 01, 2024 (157) |
159 | ClinVar | RCV000782732.11 | Nov 01, 2024 (157) |
160 | ClinVar | RCV000782733.10 | Nov 01, 2024 (157) |
161 | ClinVar | RCV000782792.11 | Nov 01, 2024 (157) |
162 | ClinVar | RCV000782857.11 | Nov 01, 2024 (157) |
163 | ClinVar | RCV000782858.11 | Nov 01, 2024 (157) |
164 | ClinVar | RCV000782859.11 | Nov 01, 2024 (157) |
165 | ClinVar | RCV000782860.11 | Nov 01, 2024 (157) |
166 | ClinVar | RCV000782861.11 | Nov 01, 2024 (157) |
167 | ClinVar | RCV000782862.11 | Nov 01, 2024 (157) |
168 | ClinVar | RCV000782863.11 | Nov 01, 2024 (157) |
169 | ClinVar | RCV000782864.11 | Nov 01, 2024 (157) |
170 | ClinVar | RCV000782992.10 | Nov 01, 2024 (157) |
171 | ClinVar | RCV000782993.10 | Nov 01, 2024 (157) |
172 | ClinVar | RCV000782994.10 | Nov 01, 2024 (157) |
173 | ClinVar | RCV000782995.10 | Nov 01, 2024 (157) |
174 | ClinVar | RCV000782996.10 | Nov 01, 2024 (157) |
175 | ClinVar | RCV000782997.10 | Nov 01, 2024 (157) |
176 | ClinVar | RCV000782998.10 | Nov 01, 2024 (157) |
177 | ClinVar | RCV000782999.10 | Nov 01, 2024 (157) |
178 | ClinVar | RCV000783000.10 | Nov 01, 2024 (157) |
179 | ClinVar | RCV000783049.11 | Nov 01, 2024 (157) |
180 | ClinVar | RCV000783050.11 | Nov 01, 2024 (157) |
181 | ClinVar | RCV000783051.11 | Nov 01, 2024 (157) |
182 | ClinVar | RCV000783052.11 | Nov 01, 2024 (157) |
183 | ClinVar | RCV000783053.11 | Nov 01, 2024 (157) |
184 | ClinVar | RCV000783054.11 | Nov 01, 2024 (157) |
185 | ClinVar | RCV000783055.11 | Nov 01, 2024 (157) |
186 | ClinVar | RCV000783056.11 | Nov 01, 2024 (157) |
187 | ClinVar | RCV000783071.10 | Nov 01, 2024 (157) |
188 | ClinVar | RCV000783077.11 | Nov 01, 2024 (157) |
189 | ClinVar | RCV000783078.11 | Nov 01, 2024 (157) |
190 | ClinVar | RCV000783079.11 | Nov 01, 2024 (157) |
191 | ClinVar | RCV000783087.11 | Nov 01, 2024 (157) |
192 | ClinVar | RCV000783090.10 | Nov 01, 2024 (157) |
193 | ClinVar | RCV000783091.10 | Nov 01, 2024 (157) |
194 | ClinVar | RCV000783092.10 | Nov 01, 2024 (157) |
195 | ClinVar | RCV000783093.10 | Nov 01, 2024 (157) |
196 | ClinVar | RCV000783097.11 | Nov 01, 2024 (157) |
197 | ClinVar | RCV000783101.11 | Nov 01, 2024 (157) |
198 | ClinVar | RCV000783112.11 | Nov 01, 2024 (157) |
199 | ClinVar | RCV000783122.11 | Nov 01, 2024 (157) |
200 | ClinVar | RCV000783123.11 | Nov 01, 2024 (157) |
201 | ClinVar | RCV000783131.11 | Nov 01, 2024 (157) |
202 | ClinVar | RCV000783171.10 | Nov 01, 2024 (157) |
203 | ClinVar | RCV000783187.10 | Nov 01, 2024 (157) |
204 | ClinVar | RCV000783188.10 | Nov 01, 2024 (157) |
205 | ClinVar | RCV000783189.10 | Nov 01, 2024 (157) |
206 | ClinVar | RCV000783190.10 | Nov 01, 2024 (157) |
207 | ClinVar | RCV000783191.10 | Nov 01, 2024 (157) |
208 | ClinVar | RCV000783223.11 | Nov 01, 2024 (157) |
209 | ClinVar | RCV000783254.11 | Nov 01, 2024 (157) |
210 | ClinVar | RCV000783255.11 | Nov 01, 2024 (157) |
211 | ClinVar | RCV000783256.11 | Nov 01, 2024 (157) |
212 | ClinVar | RCV000783257.11 | Nov 01, 2024 (157) |
213 | ClinVar | RCV000783258.11 | Nov 01, 2024 (157) |
214 | ClinVar | RCV000783259.11 | Nov 01, 2024 (157) |
215 | ClinVar | RCV000783260.11 | Nov 01, 2024 (157) |
216 | ClinVar | RCV000783325.10 | Nov 01, 2024 (157) |
217 | ClinVar | RCV000783326.10 | Nov 01, 2024 (157) |
218 | ClinVar | RCV000783372.11 | Nov 01, 2024 (157) |
219 | ClinVar | RCV000783384.11 | Nov 01, 2024 (157) |
220 | ClinVar | RCV000783401.11 | Nov 01, 2024 (157) |
221 | ClinVar | RCV000783402.11 | Nov 01, 2024 (157) |
222 | ClinVar | RCV000783403.11 | Nov 01, 2024 (157) |
223 | ClinVar | RCV000783404.11 | Nov 01, 2024 (157) |
224 | ClinVar | RCV000783405.11 | Nov 01, 2024 (157) |
225 | ClinVar | RCV000783406.11 | Nov 01, 2024 (157) |
226 | ClinVar | RCV000783472.10 | Nov 01, 2024 (157) |
227 | ClinVar | RCV000783473.10 | Nov 01, 2024 (157) |
228 | ClinVar | RCV000783512.11 | Nov 01, 2024 (157) |
229 | ClinVar | RCV000783513.11 | Nov 01, 2024 (157) |
230 | ClinVar | RCV000783523.10 | Nov 01, 2024 (157) |
231 | ClinVar | RCV000783524.10 | Nov 01, 2024 (157) |
232 | ClinVar | RCV000783525.10 | Nov 01, 2024 (157) |
233 | ClinVar | RCV000783526.10 | Nov 01, 2024 (157) |
234 | ClinVar | RCV000783527.10 | Nov 01, 2024 (157) |
235 | ClinVar | RCV000783528.10 | Nov 01, 2024 (157) |
236 | ClinVar | RCV000783530.11 | Nov 01, 2024 (157) |
237 | ClinVar | RCV000783536.11 | Nov 01, 2024 (157) |
238 | ClinVar | RCV000783557.11 | Nov 01, 2024 (157) |
239 | ClinVar | RCV000783558.11 | Nov 01, 2024 (157) |
240 | ClinVar | RCV000783559.11 | Nov 01, 2024 (157) |
241 | ClinVar | RCV000783568.11 | Nov 01, 2024 (157) |
242 | ClinVar | RCV000783587.10 | Nov 01, 2024 (157) |
243 | ClinVar | RCV000783588.10 | Nov 01, 2024 (157) |
244 | ClinVar | RCV000783617.10 | Nov 01, 2024 (157) |
245 | ClinVar | RCV000783622.10 | Nov 01, 2024 (157) |
246 | ClinVar | RCV000783630.10 | Nov 01, 2024 (157) |
247 | ClinVar | RCV000783631.11 | Nov 01, 2024 (157) |
248 | ClinVar | RCV000783632.10 | Nov 01, 2024 (157) |
249 | ClinVar | RCV000783633.10 | Nov 01, 2024 (157) |
250 | ClinVar | RCV000783634.10 | Nov 01, 2024 (157) |
251 | ClinVar | RCV000783635.10 | Nov 01, 2024 (157) |
252 | ClinVar | RCV000783649.11 | Nov 01, 2024 (157) |
253 | ClinVar | RCV000783666.11 | Nov 01, 2024 (157) |
254 | ClinVar | RCV000783667.11 | Nov 01, 2024 (157) |
255 | ClinVar | RCV000783668.10 | Nov 01, 2024 (157) |
256 | ClinVar | RCV000783669.10 | Nov 01, 2024 (157) |
257 | ClinVar | RCV000783670.11 | Nov 01, 2024 (157) |
258 | ClinVar | RCV000783671.11 | Nov 01, 2024 (157) |
259 | ClinVar | RCV000783676.10 | Nov 01, 2024 (157) |
260 | ClinVar | RCV000783682.10 | Nov 01, 2024 (157) |
261 | ClinVar | RCV000783683.10 | Nov 01, 2024 (157) |
262 | ClinVar | RCV000783735.11 | Nov 01, 2024 (157) |
263 | ClinVar | RCV000783759.10 | Nov 01, 2024 (157) |
264 | ClinVar | RCV000783760.10 | Nov 01, 2024 (157) |
265 | ClinVar | RCV000783761.10 | Nov 01, 2024 (157) |
266 | ClinVar | RCV000783762.10 | Nov 01, 2024 (157) |
267 | ClinVar | RCV000783763.10 | Nov 01, 2024 (157) |
268 | ClinVar | RCV000783764.10 | Nov 01, 2024 (157) |
269 | ClinVar | RCV000783765.10 | Nov 01, 2024 (157) |
270 | ClinVar | RCV000783766.10 | Nov 01, 2024 (157) |
271 | ClinVar | RCV000783767.10 | Nov 01, 2024 (157) |
272 | ClinVar | RCV000783768.11 | Nov 01, 2024 (157) |
273 | ClinVar | RCV000783783.11 | Nov 01, 2024 (157) |
274 | ClinVar | RCV000783787.11 | Nov 01, 2024 (157) |
275 | ClinVar | RCV000783788.11 | Nov 01, 2024 (157) |
276 | ClinVar | RCV000783821.11 | Nov 01, 2024 (157) |
277 | ClinVar | RCV000783822.11 | Nov 01, 2024 (157) |
278 | ClinVar | RCV000783826.11 | Nov 01, 2024 (157) |
279 | ClinVar | RCV000783827.11 | Nov 01, 2024 (157) |
280 | ClinVar | RCV000783828.11 | Nov 01, 2024 (157) |
281 | ClinVar | RCV000783829.11 | Nov 01, 2024 (157) |
282 | ClinVar | RCV000783830.11 | Nov 01, 2024 (157) |
283 | ClinVar | RCV000783848.11 | Nov 01, 2024 (157) |
284 | ClinVar | RCV000783849.11 | Nov 01, 2024 (157) |
285 | ClinVar | RCV000783888.10 | Nov 01, 2024 (157) |
286 | ClinVar | RCV000783889.10 | Nov 01, 2024 (157) |
287 | ClinVar | RCV000783890.10 | Nov 01, 2024 (157) |
288 | ClinVar | RCV000783891.10 | Nov 01, 2024 (157) |
289 | ClinVar | RCV000783892.10 | Nov 01, 2024 (157) |
290 | ClinVar | RCV000783926.10 | Nov 01, 2024 (157) |
291 | ClinVar | RCV000783927.10 | Nov 01, 2024 (157) |
292 | ClinVar | RCV000783950.10 | Nov 01, 2024 (157) |
293 | ClinVar | RCV000783958.11 | Nov 01, 2024 (157) |
294 | ClinVar | RCV000783959.10 | Nov 01, 2024 (157) |
295 | ClinVar | RCV000783960.10 | Nov 01, 2024 (157) |
296 | ClinVar | RCV000783961.10 | Nov 01, 2024 (157) |
297 | ClinVar | RCV000783962.10 | Nov 01, 2024 (157) |
298 | ClinVar | RCV000783963.10 | Nov 01, 2024 (157) |
299 | ClinVar | RCV000783964.10 | Nov 01, 2024 (157) |
300 | ClinVar | RCV000783965.10 | Nov 01, 2024 (157) |
301 | ClinVar | RCV000783985.12 | Nov 01, 2024 (157) |
302 | ClinVar | RCV000783986.12 | Nov 01, 2024 (157) |
303 | ClinVar | RCV000784024.11 | Nov 01, 2024 (157) |
304 | ClinVar | RCV000784049.11 | Nov 01, 2024 (157) |
305 | ClinVar | RCV000784050.11 | Nov 01, 2024 (157) |
306 | ClinVar | RCV000784083.11 | Nov 01, 2024 (157) |
307 | ClinVar | RCV000784084.11 | Nov 01, 2024 (157) |
308 | ClinVar | RCV000784085.11 | Nov 01, 2024 (157) |
309 | ClinVar | RCV000784086.11 | Nov 01, 2024 (157) |
310 | ClinVar | RCV000784087.11 | Nov 01, 2024 (157) |
311 | ClinVar | RCV000784088.11 | Nov 01, 2024 (157) |
312 | ClinVar | RCV000784089.11 | Nov 01, 2024 (157) |
313 | ClinVar | RCV000784090.11 | Nov 01, 2024 (157) |
314 | ClinVar | RCV000784222.10 | Nov 01, 2024 (157) |
315 | ClinVar | RCV000784223.10 | Nov 01, 2024 (157) |
316 | ClinVar | RCV000784224.10 | Nov 01, 2024 (157) |
317 | ClinVar | RCV000784225.10 | Nov 01, 2024 (157) |
318 | ClinVar | RCV000784226.10 | Nov 01, 2024 (157) |
319 | ClinVar | RCV000784227.10 | Nov 01, 2024 (157) |
320 | ClinVar | RCV000784228.10 | Nov 01, 2024 (157) |
321 | ClinVar | RCV000784229.10 | Nov 01, 2024 (157) |
322 | ClinVar | RCV000784230.10 | Nov 01, 2024 (157) |
323 | ClinVar | RCV000784231.10 | Nov 01, 2024 (157) |
324 | ClinVar | RCV000784232.10 | Nov 01, 2024 (157) |
325 | ClinVar | RCV000784285.11 | Nov 01, 2024 (157) |
326 | ClinVar | RCV000784286.11 | Nov 01, 2024 (157) |
327 | ClinVar | RCV000784287.11 | Nov 01, 2024 (157) |
328 | ClinVar | RCV000784288.11 | Nov 01, 2024 (157) |
329 | ClinVar | RCV000784315.11 | Nov 01, 2024 (157) |
330 | ClinVar | RCV000784322.10 | Nov 01, 2024 (157) |
331 | ClinVar | RCV000784325.10 | Nov 01, 2024 (157) |
332 | ClinVar | RCV000784326.10 | Nov 01, 2024 (157) |
333 | ClinVar | RCV000784332.11 | Nov 01, 2024 (157) |
334 | ClinVar | RCV000784336.11 | Nov 01, 2024 (157) |
335 | ClinVar | RCV000784353.11 | Nov 01, 2024 (157) |
336 | ClinVar | RCV000784359.11 | Nov 01, 2024 (157) |
337 | ClinVar | RCV000784386.10 | Nov 01, 2024 (157) |
338 | ClinVar | RCV000784387.10 | Nov 01, 2024 (157) |
339 | ClinVar | RCV000784388.10 | Nov 01, 2024 (157) |
340 | ClinVar | RCV000784389.10 | Nov 01, 2024 (157) |
341 | ClinVar | RCV000784390.10 | Nov 01, 2024 (157) |
342 | ClinVar | RCV000784391.10 | Nov 01, 2024 (157) |
343 | ClinVar | RCV000784415.10 | Nov 01, 2024 (157) |
344 | ClinVar | RCV000784421.10 | Nov 01, 2024 (157) |
345 | ClinVar | RCV000784422.10 | Nov 01, 2024 (157) |
346 | ClinVar | RCV000784423.10 | Nov 01, 2024 (157) |
347 | ClinVar | RCV000784424.11 | Nov 01, 2024 (157) |
348 | ClinVar | RCV000784433.12 | Nov 01, 2024 (157) |
349 | ClinVar | RCV000784435.11 | Nov 01, 2024 (157) |
350 | ClinVar | RCV000784436.11 | Nov 01, 2024 (157) |
351 | ClinVar | RCV000784437.11 | Nov 01, 2024 (157) |
352 | ClinVar | RCV000784438.11 | Nov 01, 2024 (157) |
353 | ClinVar | RCV000784439.11 | Nov 01, 2024 (157) |
354 | ClinVar | RCV000784440.11 | Nov 01, 2024 (157) |
355 | ClinVar | RCV000784472.11 | Nov 01, 2024 (157) |
356 | ClinVar | RCV000784489.11 | Nov 01, 2024 (157) |
357 | ClinVar | RCV000784549.12 | Nov 01, 2024 (157) |
358 | ClinVar | RCV000784557.10 | Nov 01, 2024 (157) |
359 | ClinVar | RCV000784558.10 | Nov 01, 2024 (157) |
360 | ClinVar | RCV000784559.10 | Nov 01, 2024 (157) |
361 | ClinVar | RCV000784560.10 | Nov 01, 2024 (157) |
362 | ClinVar | RCV000784561.10 | Nov 01, 2024 (157) |
363 | ClinVar | RCV000784562.10 | Nov 01, 2024 (157) |
364 | ClinVar | RCV000784563.10 | Nov 01, 2024 (157) |
365 | ClinVar | RCV000784564.10 | Nov 01, 2024 (157) |
366 | ClinVar | RCV000784638.11 | Nov 01, 2024 (157) |
367 | ClinVar | RCV000784639.11 | Nov 01, 2024 (157) |
368 | ClinVar | RCV000784705.10 | Nov 01, 2024 (157) |
369 | ClinVar | RCV000784706.10 | Nov 01, 2024 (157) |
370 | ClinVar | RCV000784707.10 | Nov 01, 2024 (157) |
371 | ClinVar | RCV000784708.10 | Nov 01, 2024 (157) |
372 | ClinVar | RCV000784709.10 | Nov 01, 2024 (157) |
373 | ClinVar | RCV000784710.10 | Nov 01, 2024 (157) |
374 | ClinVar | RCV000784711.10 | Nov 01, 2024 (157) |
375 | ClinVar | RCV000784712.10 | Nov 01, 2024 (157) |
376 | ClinVar | RCV000784737.10 | Nov 01, 2024 (157) |
377 | ClinVar | RCV000784745.11 | Nov 01, 2024 (157) |
378 | ClinVar | RCV000784752.11 | Nov 01, 2024 (157) |
379 | ClinVar | RCV000784753.11 | Nov 01, 2024 (157) |
380 | ClinVar | RCV000784759.10 | Nov 01, 2024 (157) |
381 | ClinVar | RCV000784763.11 | Nov 01, 2024 (157) |
382 | ClinVar | RCV000784773.11 | Nov 01, 2024 (157) |
383 | ClinVar | RCV000784779.11 | Nov 01, 2024 (157) |
384 | ClinVar | RCV000784789.11 | Nov 01, 2024 (157) |
385 | ClinVar | RCV000784809.10 | Nov 01, 2024 (157) |
386 | ClinVar | RCV000784810.10 | Nov 01, 2024 (157) |
387 | ClinVar | RCV000784811.10 | Nov 01, 2024 (157) |
388 | ClinVar | RCV000784812.10 | Nov 01, 2024 (157) |
389 | ClinVar | RCV000784851.10 | Nov 01, 2024 (157) |
390 | ClinVar | RCV000784856.10 | Nov 01, 2024 (157) |
391 | ClinVar | RCV000784857.10 | Nov 01, 2024 (157) |
392 | ClinVar | RCV000784868.11 | Nov 01, 2024 (157) |
393 | ClinVar | RCV000784869.11 | Nov 01, 2024 (157) |
394 | ClinVar | RCV000784870.11 | Nov 01, 2024 (157) |
395 | ClinVar | RCV000784871.11 | Nov 01, 2024 (157) |
396 | ClinVar | RCV000784872.11 | Nov 01, 2024 (157) |
397 | ClinVar | RCV000784873.11 | Nov 01, 2024 (157) |
History tab displays RefSNPs (Associated ID) from previous builds (Build) that now support the current RefSNP, and the dates, when the history was updated for each Associated ID (History Updated).
Associated ID | History Updated (Build) |
---|---|
rs17442305 | Oct 08, 2004 (123) |
rs17879736 | Mar 10, 2006 (126) |
rs117093607 | Aug 16, 2010 (132) |
Submission IDs | Observation SPDI | Canonical SPDI | Source RSIDs |
---|---|---|---|
ss8624255696 | NC_000010.10:96521656:C:A | NC_000010.11:94761899:C:A | (self) |
ss2137495309 | NC_000010.11:94761899:C:A | NC_000010.11:94761899:C:A | (self) |
ss158145862 | NT_030059.13:47326120:C:A | NC_000010.11:94761899:C:A | (self) |
ss113672527, ss170776165, ss280732303, ss286243779, ss290909204, ss1597477658 | NC_000010.9:96511646:C:T | NC_000010.11:94761899:C:T | (self) |
51054405, 28345299, 20116216, 2282719, 12639199, 30132836, 10870338, 188493, 13212254, 26844258, 7106588, 28345299, 6294330, ss224884168, ss235292619, ss562142848, ss657183816, ss987804334, ss1077215281, ss1338622991, ss1426411098, ss1575296670, ss1625195760, ss1668189793, ss1931170324, ss2026313586, ss2154590234, ss2698842972, ss2892126623, ss3006965807, ss3349261213, ss3674377968, ss3737585473, ss3748468190, ss3832276807, ss3874827278, ss3922955442, ss3984639028, ss6253826032, ss6307409869, ss6322395594, ss6326442641, ss6332060631, ss6343187231, ss6349787529, ss8198968530, ss8237481891, ss8237481892, ss8237481893, ss8395322415, ss8510129323, ss8624255696, ss8649885623, ss8799403694, ss8824807337, ss8847378107, ss8847605615, ss8941172158, ss8981728040, ss8982151818 | NC_000010.10:96521656:C:T | NC_000010.11:94761899:C:T | (self) |
RCV000326411.15, RCV000782438.10, RCV000782443.10, RCV000782446.11, RCV000782447.11, RCV000782451.10, RCV000782454.10, RCV000782459.11, RCV000782460.10, RCV000782461.10, RCV000782462.12, RCV000782463.11, RCV000782492.10, RCV000782493.10, RCV000782505.11, RCV000782506.11, RCV000782507.11, RCV000782508.11, RCV000782509.11, RCV000782514.11, RCV000782515.11, RCV000782524.11, RCV000782525.11, RCV000782529.10, RCV000782534.10, RCV000782535.10, RCV000782536.10, RCV000782537.10, RCV000782544.11, RCV000782548.11, RCV000782549.11, RCV000782553.11, RCV000782575.11, RCV000782576.11, RCV000782600.11, RCV000782658.10, RCV000782659.10, RCV000782660.10, RCV000782661.10, RCV000782662.10, RCV000782663.10, RCV000782664.10, RCV000782713.10, RCV000782714.10, RCV000782724.10, RCV000782726.10, RCV000782727.10, RCV000782728.10, RCV000782729.10, RCV000782730.10, RCV000782731.10, RCV000782732.11, RCV000782733.10, RCV000782792.11, RCV000782857.11, RCV000782858.11, RCV000782859.11, RCV000782860.11, RCV000782861.11, RCV000782862.11, RCV000782863.11, RCV000782864.11, RCV000782992.10, RCV000782993.10, RCV000782994.10, RCV000782995.10, RCV000782996.10, RCV000782997.10, RCV000782998.10, RCV000782999.10, RCV000783000.10, RCV000783049.11, RCV000783050.11, RCV000783051.11, RCV000783052.11, RCV000783053.11, RCV000783054.11, RCV000783055.11, RCV000783056.11, RCV000783071.10, RCV000783077.11, RCV000783078.11, RCV000783079.11, RCV000783087.11, RCV000783090.10, RCV000783091.10, RCV000783092.10, RCV000783093.10, RCV000783097.11, RCV000783101.11, RCV000783112.11, RCV000783122.11, RCV000783123.11, RCV000783131.11, RCV000783171.10, RCV000783187.10, RCV000783188.10, RCV000783189.10, RCV000783190.10, RCV000783191.10, RCV000783223.11, RCV000783254.11, RCV000783255.11, RCV000783256.11, RCV000783257.11, RCV000783258.11, RCV000783259.11, RCV000783260.11, RCV000783325.10, RCV000783326.10, RCV000783372.11, RCV000783384.11, RCV000783401.11, RCV000783402.11, RCV000783403.11, RCV000783404.11, RCV000783405.11, RCV000783406.11, RCV000783472.10, RCV000783473.10, RCV000783512.11, RCV000783513.11, RCV000783523.10, RCV000783524.10, RCV000783525.10, RCV000783526.10, RCV000783527.10, RCV000783528.10, RCV000783530.11, RCV000783536.11, RCV000783557.11, RCV000783558.11, RCV000783559.11, RCV000783568.11, RCV000783587.10, RCV000783588.10, RCV000783617.10, RCV000783622.10, RCV000783630.10, RCV000783631.11, RCV000783632.10, RCV000783633.10, RCV000783634.10, RCV000783635.10, RCV000783649.11, RCV000783666.11, RCV000783667.11, RCV000783668.10, RCV000783669.10, RCV000783670.11, RCV000783671.11, RCV000783676.10, RCV000783682.10, RCV000783683.10, RCV000783735.11, RCV000783759.10, RCV000783760.10, RCV000783761.10, RCV000783762.10, RCV000783763.10, RCV000783764.10, RCV000783765.10, RCV000783766.10, RCV000783767.10, RCV000783768.11, RCV000783783.11, RCV000783787.11, RCV000783788.11, RCV000783821.11, RCV000783822.11, RCV000783826.11, RCV000783827.11, RCV000783828.11, RCV000783829.11, RCV000783830.11, RCV000783848.11, RCV000783849.11, RCV000783888.10, RCV000783889.10, RCV000783890.10, RCV000783891.10, RCV000783892.10, RCV000783926.10, RCV000783927.10, RCV000783950.10, RCV000783958.11, RCV000783959.10, RCV000783960.10, RCV000783961.10, RCV000783962.10, RCV000783963.10, RCV000783964.10, RCV000783965.10, RCV000783985.12, RCV000783986.12, RCV000784024.11, RCV000784049.11, RCV000784050.11, RCV000784083.11, RCV000784084.11, RCV000784085.11, RCV000784086.11, RCV000784087.11, RCV000784088.11, RCV000784089.11, RCV000784090.11, RCV000784222.10, RCV000784223.10, RCV000784224.10, RCV000784225.10, RCV000784226.10, RCV000784227.10, RCV000784228.10, RCV000784229.10, RCV000784230.10, RCV000784231.10, RCV000784232.10, RCV000784285.11, RCV000784286.11, RCV000784287.11, RCV000784288.11, RCV000784315.11, RCV000784322.10, RCV000784325.10, RCV000784326.10, RCV000784332.11, RCV000784336.11, RCV000784353.11, RCV000784359.11, RCV000784386.10, RCV000784387.10, RCV000784388.10, RCV000784389.10, RCV000784390.10, RCV000784391.10, RCV000784415.10, RCV000784421.10, RCV000784422.10, RCV000784423.10, RCV000784424.11, RCV000784433.12, RCV000784435.11, RCV000784436.11, RCV000784437.11, RCV000784438.11, RCV000784439.11, RCV000784440.11, RCV000784472.11, RCV000784489.11, RCV000784549.12, RCV000784557.10, RCV000784558.10, RCV000784559.10, RCV000784560.10, RCV000784561.10, RCV000784562.10, RCV000784563.10, RCV000784564.10, RCV000784638.11, RCV000784639.11, RCV000784705.10, RCV000784706.10, RCV000784707.10, RCV000784708.10, RCV000784709.10, RCV000784710.10, RCV000784711.10, RCV000784712.10, RCV000784737.10, RCV000784745.11, RCV000784752.11, RCV000784753.11, RCV000784759.10, RCV000784763.11, RCV000784773.11, RCV000784779.11, RCV000784789.11, RCV000784809.10, RCV000784810.10, RCV000784811.10, RCV000784812.10, RCV000784851.10, RCV000784856.10, RCV000784857.10, RCV000784868.11, RCV000784869.11, RCV000784870.11, RCV000784871.11, RCV000784872.11, RCV000784873.11, 67090069, 387010091, 468169, 24836148, 32140551, 131576346, 78168267, 2625147327, ss1457608700, ss2137544432, ss2137544462, ss2177147096, ss3026946906, ss3649441543, ss3690461668, ss3813834340, ss3968458147, ss4862622612, ss6114200526, ss6349997713, ss6382288653, ss6859874352, ss8285087471, ss8314429322, ss8480547542, ss8579564134, ss8745186048, ss8811792280, ss8849697092, ss8880085382 | NC_000010.11:94761899:C:T | NC_000010.11:94761899:C:T | (self) |
ss18627820, ss20629041 | NT_030059.11:15270182:C:T | NC_000010.11:94761899:C:T | (self) |
ss24554293, ss28531395, ss39719499, ss97675639, ss137888305, ss158145861, ss158145863 | NT_030059.13:47326120:C:T | NC_000010.11:94761899:C:T | (self) |
Publications tab displays PubMed articles citing the variation as a listing of PMID, Title, Author, Year, Journal, ordered by Year, descending.
PMID | Title | Author | Year | Journal |
---|---|---|---|---|
17048007 | Association of warfarin dose with genes involved in its action and metabolism. | Wadelius M et al. | 2007 | Human genetics |
17625515 | Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. | Rudberg I et al. | 2008 | Clinical pharmacology and therapeutics |
18521743 | CYP2C19*17 is associated with decreased breast cancer risk. | Justenhoven C et al. | 2009 | Breast cancer research and treatment |
19136640 | Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test. | Desta Z et al. | 2009 | The Journal of pharmacology and experimental therapeutics |
19463375 | The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. | Gladding P et al. | 2008 | JACC. Cardiovascular interventions |
19706858 | Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. | Shuldiner AR et al. | 2009 | JAMA |
20083681 | Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. | Sibbing D et al. | 2010 | Circulation |
20492469 | Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. | Sibbing D et al. | 2010 | Journal of thrombosis and haemostasis |
20531370 | Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. | de Vos A et al. | 2011 | The pharmacogenomics journal |
20801498 | Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. | Wallentin L et al. | 2010 | Lancet (London, England) |
20826260 | Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. | Tiroch KA et al. | 2010 | American heart journal |
20847277 | Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. | Baak-Pablo R et al. | 2010 | The Journal of molecular diagnostics |
20921971 | Mapping genes that predict treatment outcome in admixed populations. | Baye TM et al. | 2010 | The pharmacogenomics journal |
21071160 | Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population. | Shi Y et al. | 2011 | Forensic science international |
21172166 | Pharmacogenetics of antidepressant response. | Porcelli S et al. | 2011 | Journal of psychiatry & neuroscience |
21192344 | CYP2C19 variation and citalopram response. | Mrazek DA et al. | 2011 | Pharmacogenetics and genomics |
21247447 | CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. | Santos PC et al. | 2011 | BMC medical genetics |
21358751 | Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. | Scott SA et al. | 2012 | The pharmacogenomics journal |
21392617 | The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. | Gurbel PA et al. | 2011 | American heart journal |
21480951 | Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. | Lim JS et al. | 2011 | British journal of clinical pharmacology |
21497341 | High-density fine-mapping of a chromosome 10q26 linkage peak suggests association between endometriosis and variants close to CYP2C19. | Painter JN et al. | 2011 | Fertility and sterility |
21546862 | PharmGKB summary: citalopram pharmacokinetics pathway. | Sangkuhl K et al. | 2011 | Pharmacogenetics and genomics |
21712189 | Analysis of pharmacogenetic traits in two distinct South African populations. | Ikediobi O et al. | 2011 | Human genomics |
21716271 | Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. | Scott SA et al. | 2011 | Clinical pharmacology and therapeutics |
21816733 | Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. | Bauer T et al. | 2011 | BMJ (Clinical research ed.) |
21918509 | Pharmacogenomics: application to the management of cardiovascular disease. | Johnson JA et al. | 2011 | Clinical pharmacology and therapeutics |
22028352 | Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. | Cayla G et al. | 2011 | JAMA |
22190063 | Predicting clopidogrel response using DNA samples linked to an electronic health record. | Delaney JT et al. | 2012 | Clinical pharmacology and therapeutics |
22228204 | The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. | Harmsze AM et al. | 2012 | Pharmacogenetics and genomics |
22462746 | CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. | Chan MY et al. | 2012 | Pharmacogenomics |
22491019 | Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. | Martis S et al. | 2013 | The pharmacogenomics journal |
22704413 | Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel. | Dai ZL et al. | 2012 | Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine |
22723959 | Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population. | Chen DY et al. | 2012 | PloS one |
22784880 | Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. | Wiese MD et al. | 2012 | Arthritis research & therapy |
22879966 | Systematic testing of literature reported genetic variation associated with coronary restenosis: results of the GENDER Study. | Verschuren JJ et al. | 2012 | PloS one |
22955794 | Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. | Subraja K et al. | 2013 | European journal of clinical pharmacology |
22990067 | Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. | Wu H et al. | 2012 | Pharmacogenetics and genomics |
22992668 | Pharmacogenomics knowledge for personalized medicine. | Whirl-Carrillo M et al. | 2012 | Clinical pharmacology and therapeutics |
23133420 | Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin. | Suarez-Kurtz G et al. | 2012 | Frontiers in pharmacology |
23226154 | Polymorphisms of Phase I and Phase II Enzymes and Breast Cancer Risk. | Justenhoven C et al. | 2012 | Frontiers in genetics |
23364775 | Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. | Carlquist JF et al. | 2013 | Thrombosis and haemostasis |
23697979 | Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? | Perry CG et al. | 2013 | Journal of human genetics |
23698643 | Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. | Scott SA et al. | 2013 | Clinical pharmacology and therapeutics |
23726091 | Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. | Zhang L et al. | 2013 | Thrombosis research |
23797323 | Pharmacogenomics of anti-platelet and anti-coagulation therapy. | Fisch AS et al. | 2013 | Current cardiology reports |
23809542 | The CYP2C19*17 variant is not independently associated with clopidogrel response. | Lewis JP et al. | 2013 | Journal of thrombosis and haemostasis |
23810503 | Comparison of high-resolution melting analysis, TaqMan Allelic discrimination assay, and sanger sequencing for Clopidogrel efficacy genotyping in routine molecular diagnostics. | Zhang L et al. | 2013 | The Journal of molecular diagnostics |
23922007 | Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention. | Park MW et al. | 2013 | Pharmacogenetics and genomics |
24019397 | CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina. | Kim HS et al. | 2013 | Circulation. Cardiovascular genetics |
24519754 | CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity. | Burns KE et al. | 2014 | Cancer chemotherapy and pharmacology |
24762860 | Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction. | Cresci S et al. | 2014 | Circulation. Cardiovascular genetics |
24796765 | Common variants in the CYP2C19 gene are associated with susceptibility to endometriosis. | Painter JN et al. | 2014 | Fertility and sterility |
24944790 | Screening for 392 polymorphisms in 141 pharmacogenes. | Kim JY et al. | 2014 | Biomedical reports |
25051347 | Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention. | Siller-Matula JM et al. | 2014 | PloS one |
25419701 | Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations. | Bonifaz-Peña V et al. | 2014 | PloS one |
25714468 | A systematic approach to the reporting of medically relevant findings from whole genome sequencing. | McLaughlin HM et al. | 2014 | BMC medical genetics |
25897256 | Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. | Beitelshees AL et al. | 2015 | Pharmacogenomics and personalized medicine |
26323597 | Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. | Shirasaka Y et al. | 2016 | The pharmacogenomics journal |
26757134 | Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population. | Khalil BM et al. | 2016 | Clinical and translational science |
26773420 | Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma. | Veal GJ et al. | 2016 | European journal of cancer (Oxford, England |
26781306 | Genotype‑phenotype analysis of CYP2C19 in the Tibetan population and its potential clinical implications in drug therapy. | Jin T et al. | 2016 | Molecular medicine reports |
26785747 | Polymorphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan. | Iskakova AN et al. | 2016 | BMC genetics |
26858644 | Cross-Comparison of Exome Analysis, Next-Generation Sequencing of Amplicons, and the iPLEX(®) ADME PGx Panel for Pharmacogenomic Profiling. | Chua EW et al. | 2016 | Frontiers in pharmacology |
26870959 | Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting. | Li XQ et al. | 2016 | PloS one |
27002825 | Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide. | Audemard-Verger A et al. | 2016 | PloS one |
27171561 | Liver Function Test Abnormalities in Depressed Patients Treated with Antidepressants: A Real-World Systematic Observational Study in Psychiatric Settings. | Voican CS et al. | 2016 | PloS one |
27249515 | Evidence for extensive pleiotropy among pharmacogenes. | Oetjens MT et al. | 2016 | Pharmacogenomics |
27277665 | Genetic risk factors for restenosis after percutaneous coronary intervention in Kazakh population. | Zholdybayeva EV et al. | 2016 | Human genomics |
27368038 | CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents. | Choi IJ et al. | 2016 | Medicine |
27529241 | The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key? | Daud AN et al. | 2016 | International journal of molecular sciences |
27636550 | A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. | Mizzi C et al. | 2016 | PloS one |
27798644 | Detection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing Data. | Ang GY et al. | 2016 | PloS one |
28378544 | Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers. | Park S et al. | 2017 | Journal of Korean medical science |
29033601 | Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. | Denisenko NP et al. | 2017 | Pharmacogenomics and personalized medicine |
29167499 | A Novel Multiplex HRM Assay to Detect Clopidogrel Resistance. | Zhang L et al. | 2017 | Scientific reports |
29193749 | Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years. | Borobia AM et al. | 2018 | Clinical and translational science |
29260275 | Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. | Novkovic M et al. | 2018 | European journal of clinical pharmacology |
29681089 | Genetic variation in biotransformation enzymes, air pollution exposures, and risk of spina bifida. | Padula AM et al. | 2018 | American journal of medical genetics. Part A |
29756345 | Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition. | Kharasch ED et al. | 2019 | Clinical pharmacology and therapeutics |
29950882 | CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. | Denisenko NP et al. | 2018 | Pharmacogenomics and personalized medicine |
30068618 | Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark. | Collin LJ et al. | 2018 | BMJ open |
30093869 | Biological Predictors of Clozapine Response: A Systematic Review. | Samanaite R et al. | 2018 | Frontiers in psychiatry |
30135031 | Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. | Fabbri C et al. | 2018 | European neuropsychopharmacology |
30452466 | Characterization of ADME genes variation in Roma and 20 populations worldwide. | Škarić-Jurić T et al. | 2018 | PloS one |
30758238 | Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel. | Langaee T et al. | 2019 | Genetic testing and molecular biomarkers |
30988702 | Defining the genetic profile of endometriosis. | Vassilopoulou L et al. | 2019 | Experimental and therapeutic medicine |
31019283 | Secondary actionable findings identified by exome sequencing: expected impact on the organisation of care from the study of 700 consecutive tests. | Thauvin-Robinet C et al. | 2019 | European journal of human genetics |
31086207 | Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population. | Afsar NA et al. | 2019 | Scientific reports |
31184624 | [Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke]. | Sychev DA et al. | 2019 | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova |
31222084 | Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children. | Espinoza N et al. | 2019 | Scientific reports |
31270413 | ||||
31441095 | Development and validation of T-ARMS-PCR to detect CYP2C19*17 allele. | Jin C et al. | 2020 | Journal of clinical laboratory analysis |
31617956 | A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants. | Kanders SH et al. | 2020 | Drug development research |
31807051 | Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects. | Dorofeeva MN et al. | 2019 | Pharmacogenomics and personalized medicine |
32134726 | How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome? | Skryabin VY et al. | 2020 | Drug metabolism and personalized therapy |
32158254 | CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. | Sychev DA et al. | 2020 | Pharmacogenomics and personalized medicine |
32303955 | Clinically relevant pharmacogenetic markers in Tatars and Balkars. | Abdullaev SP et al. | 2020 | Molecular biology reports |
32392440 | The Frequency of the Minor Polymorphisms in the CYP2C19, VEGFR-2 Genes, and Clinical Outcomes in Russian and Buryat Patients with Acute Coronary Syndrome. | Zelenskaya EM et al. | 2020 | Genetic testing and molecular biomarkers |
32472697 | Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. | Verma SS et al. | 2020 | Clinical pharmacology and therapeutics |
32639515 | Bayesian Pathway Analysis for Complex Interactions. | Baurley JW et al. | 2020 | American journal of epidemiology |
32862511 | Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease. | Ma L et al. | 2020 | International journal of immunogenetics |
33124772 | Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections. | Chuwongwattana S et al. | 2020 | Pharmacology research & perspectives |
33192522 | Pleiotropic Functions of Cytochrome P450 Monooxygenase-Derived Eicosanoids in Cancer. | Luo Y et al. | 2020 | Frontiers in pharmacology |
33423267 | [Association of CYP2C19 and CYP3A5 gene polymorphisms with myocardial infarction]. | Qi L et al. | 2021 | Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics |
33519226 | Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon. | Fernandes MR et al. | 2021 | Pharmacogenomics and personalized medicine |
33569925 | Gene-environment interactions between air pollution and biotransformation enzymes and risk of birth defects. | Padula AM et al. | 2021 | Birth defects research |
33580125 | Preservation of epoxyeicosatrienoic acid bioavailability prevents renal allograft dysfunction and cardiovascular alterations in kidney transplant recipients. | Duflot T et al. | 2021 | Scientific reports |
33805706 | SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. | Zubiaur P et al. | 2021 | Journal of personalized medicine |
33995083 | Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism. | Mejía-Abril G et al. | 2021 | Frontiers in pharmacology |
34382722 | Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm. | Ndadza A et al. | 2021 | Journal of thrombosis and haemostasis |
34385834 | Individualized Drugs' Selection by Evaluation of Drug Properties, Pharmacogenomics and Clinical Parameters: Performance of a Bioinformatic Tool Compared to a Clinically Established Counselling Process. | Borro M et al. | 2021 | Pharmacogenomics and personalized medicine |
34429635 | Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population. | He C et al. | 2021 | Pharmacogenomics and personalized medicine |
34621165 | Lack of Major Involvement of Common CYP2C Gene Polymorphisms in the Risk of Developing Cross-Hypersensitivity to NSAIDs. | Macías Y et al. | 2021 | Frontiers in pharmacology |
34621706 | Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform. | Kim B et al. | 2021 | Translational and clinical pharmacology |
34690761 | Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin. | Villapalos-García G et al. | 2021 | Frontiers in pharmacology |
34920277 | Assessment of susceptibility to phthalate and DINCH exposure through CYP and UGT single nucleotide polymorphisms. | Stajnko A et al. | 2022 | Environment international |
34949935 | Genetic Polymorphisms of Very Important Pharmacogene Variants in the Blang Population from Yunnan Province in China. | Wang Y et al. | 2021 | Pharmacogenomics and personalized medicine |
34958284 | Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes. | Muyambo S et al. | 2022 | Omics |
35089958 | Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population. | Goljan E et al. | 2022 | PloS one |
35235711 | Evaluation of the relationship between polymorphisms in CYP2C19 and the single-dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study. | Zhou S et al. | 2022 | Clinical and translational science |
35664313 | Omeprazole Treatment Failure in Gastroesophageal Reflux Disease and Genetic Variation at the CYP2C Locus. | Kee PS et al. | 2022 | Frontiers in genetics |
35761855 | Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective. | Nthontho KC et al. | 2022 | Pharmacogenomics and personalized medicine |
36065758 | CYP2C8*3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride. | Campodónico DM et al. | 2022 | Clinical and translational science |
36164570 | Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard. | Alshabeeb MA et al. | 2022 | Saudi pharmaceutical journal |
36333412 | Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder. | Joas E et al. | 2023 | The pharmacogenomics journal |
The Flanks tab provides retrieving flanking sequences of a SNP on all molecules that have placements.
Genomic regions, transcripts, and products
Top▲
Help
NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.
NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.